GT Biopharma (GTBP) had the highest return since January 3, 2009 and in 2012 by a US stock, returning 3,044,698,370%.
| ASSET | % RETURN |
|---|---|
GT Biopharma (GTBP) | 3,044,698,370% |
QXO (QXO) | 1,151,950% |
Intellinetics (INLX) | 8,066.67% |
Par Pacific (PARR) | 1,900% |
Actinium Pharmaceuticals (ATNM) | 1,400% |
Vivakor (VIVK) | 1,224.46% |
Netcapital (NCPL) | 600% |
Security National Financial (SNFCA) | 487.2% |
Coda Octopus (CODA) | 470.71% |
Sarepta Therapeutics (SRPT) | 469.54% |
Consumer Portfolio Services (CPSS) | 452.86% |
Arena (AREN) | 448.14% |
Imunon (IMNN) | 376.16% |
Hovnanian Enterprises (HOV) | 366.67% |
BOS Better Online Solutions (BOSC) | 355.56% |
BioLife Solutions (BLFS) | 325% |
ACADIA Pharmaceuticals (ACAD) | 322.73% |
Harrow Health (HROW) | 306.25% |
Recon Technology (RCON) | 305.8% |
Waterstone Financial (WSBF) | 305.18% |
Milestone Scientific (MLSS) | 302.78% |
TOMI Environmental Solutions (TOMZ) | 302.14% |
Sellas Life Sciences (SLS) | 296.04% |
Patrick Industries (PATK) | 276.75% |
Paysign (PAYS) | 271.25% |
